Panel – Bench to Bedside & Back – Assessing the Benefits of a Reverse Translational Approach When Minimizing ADC Toxicities

Time: 12:00 pm
day: Conference Day 2


  • Viewing the ways toxicities present themselves clinically to consider what can be done preclinically to mitigate these effects
  • Transferring from human studies to animal studies to obtain a deeper understanding of how different ADCs are distributed across healthy tissues
  • Understanding potential biomarkers for predicting toxicities which present in humans and being able to connect this back to the pre-clinical stage
  • Navigating the concept of translating back and mechanistically blocking the toxicity in vitro